RESEARCH & TREATMENT

Many CAC2 member organizations fund essential research initiatives across the spectrum of development–from basic research through to clinical trials–and across the spectrum of topics–from data sharing to crucial medicines to psychosocial standards to survivorship. We support our members’ involvement in all aspects of research related to childhood and AYA cancer by making it easier to keep up with emerging trends and to work together more effectively.

Research is crucial to discovering better treatments, minimizing side effects, increasing quality of life during and after treatment, and, most importantly, finding cures. Our efforts are important because of the large and persistent gap between the need for funding and the money available for childhood cancer research projects.

CAC2 member organizations with a research interest or focus are encouraged to participate in the work of the CAC2 Research Interest Group. Notes from the 2019 meeting of the working group are available here. Contact Research Group Liaison Amy Weinstein at if you would like more information on how to be involved with CAC2 research initiatives.

“Talent wins games, but teamwork and intelligence win championships.” – Michael Jordan

ICRP Database
Current Projects
CAC2 Research Conference Proceedings

  • CAC2 Childhood Cancer Community News Digest (July 15-21)

    Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals and CAC2 member authors and reviewers who contributed to the white paper “Advancing Pediatric Cancer Research and Drug Development through Multi-Stakeholder Collaboration: A Framework Based on the Tovorafenib Journey.” Read about the collaborative effort that made this paper possible on the CAC2 Collaborative Achievement Blog. More frequent use of genetic testing in pediatric oncology, along with the application of advanced testing methods, holds great promise for identifying patients with CPS as well as detecting somatic variants that inform diagnosis, prognosis, and treatment. The FDA has granted [...]

  • CAC2 Collaborative Achievement–CAC2 Members Build Framework for Advancing Pediatric Cancer Research and Drug Development

    At CAC2 we love to celebrate when our members work together.  We offer congratulations to Supporting Organization Day One Biopharmaceuticals and CAC2 member authors and reviewers who contributed to the white paper "Advancing Pediatric Cancer Research and Drug Development through Multi-Stakeholder Collaboration: A Framework Based on the Tovorafenib Journey."   "Advancing Pediatric Cancer Research and Drug Development through Multi-Stakeholder Collaboration" highlights the specific collaborative efforts needed to address the limited treatment options for childhood cancer. Based on learnings from the research and development journey of tovorafenib, a treatment for pediatric low-grade glioma, the paper highlights features of successful collaborations among [...]

  • CAC2 Childhood Cancer Community News Digest (July 8-14)

    Assorted News from the Last Week: Psychological and ethical issues raised by genomic testing in paediatric care pathway, a qualitative analysis with parents and childhood cancer patients. Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. CAR-T therapy, which harnesses a person’s own immune cells, racks up some astonishing success stories against deadly brain tumours in children. Researchers has identified and located a population of stem-like cells that initiates and maintains Group 3 medulloblastoma (Gr3-MB) in the developing brain. They showed that eliminating the small population of stem-like cells present in Gr3-MB tumors led [...]